Article info
PDFReview
Rare neurological diseases: a practical approach to management
- Correspondence to Dr Krishna A Dani, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, 1345 Govan Road, Glasgow G51 4TF, UK; krishna.dani{at}glasgow.ac.uk
Citation
Rare neurological diseases: a practical approach to management
Publication history
- Received August 23, 2012
- Revised January 18, 2013
- Accepted January 28, 2013
- First published March 13, 2013.
Online issue publication
April 14, 2016
Article Versions
- Previous version (14 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
- Should rare diseases get special treatment?
- Rare childhood diseases: how should we respond?
- Estimating rare disease prevalence and costs in the USA: a cohort study approach using the Healthcare Cost Institute claims data
- Rare diseases in healthcare priority setting: should rarity matter?
- Agranulocytosis with deferiprone treatment of superficial siderosis
- Orphan drugs and the NHS: should we value rarity?
- Classical infratentorial superficial siderosis of the central nervous system: pathophysiology, clinical features and management
- Rare diseases under different levels of economic analysis: current activities, challenges and perspectives
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis